How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Rabies Vaccine (Vero Cell) For Human Use, Freeze-Dried Market
- By Vaccine Presentation: Freeze-Dried Vial, Liquid Ready-to-Use Syringe, Lyophilized Powder
- By Indication: Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP)
- By End User: Hospitals, Clinics, Public Health Centers, Travel Clinics
- By Dosage Schedule: Essen Regimen, Zagreb Regimen, Thai Red Cross Regimen
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Government Procurement
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Freeze-Dried Vial leads By Vaccine Presentation at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 280 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.170 →
- 12 Company Profiles 14 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Rabies Vaccine (Vero Cell) For Human Use, Freeze-Dried Market report
A complete, evidence-based study - 12 chapters and 117 sections covering market size, segmentation across 5 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Vaccine Presentation 3
Indication 2
End User 4
Dosage Schedule 3
Distribution Channel 3
Companies profiled
Sanofi Pasteur
GlaxoSmithKline (GSK)
Bharat Biotech
Serum Institute of India
Mundipharma
Novartis (now part of GSK)
Shantha Biotechnics (a Sanofi company)
Zydus Cadila
Biological E. Limited
InterVax
Chongqing Zhifei Biological Products
Jiangsu Taibang Biological Products
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Sanofi Pasteur
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →GlaxoSmithKline (GSK)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Bharat Biotech
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Serum Institute of India
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Mundipharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Novartis (now part of GSK)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Shantha Biotechnics (a Sanofi company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Zydus Cadila
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Biological E. Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →InterVax
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Chongqing Zhifei Biological Products
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Jiangsu Taibang Biological Products
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Vabiotech
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Bio-Manguinhos (Fiocruz)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,873M by 2033 · 3.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Freeze-Dried Vial49.8
- Liquid Ready-to-Use Syringe25.8
- Lyophilized Powder24.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$462.9M → $603.0M · 3.4%
Europe$322.7M → $451.0M · 4.3%
Asia Pacific$294.6M → $384.4M · 3.4%
Latin America$182.4M → $263.3M · 4.7%
Middle East and Africa$140.3M → $175.9M · 2.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.622026
3.632027
3.662028
3.672029
3.672030
3.682031
3.712032
3.712033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Sanofi Pasteur10.2
- GlaxoSmithKline (GSK)28.7
- Bharat Biotech9.0
- Serum Institute of India5.8
- Mundipharma11.2
- Novartis (now part of GSK)7.2
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Vaccine Presentation24.0%
Indication24.9%
End User22.4%
Dosage Schedule19.4%
Distribution Channel9.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.1
- Europe24.0
- Asia Pacific20.5
- Latin America14.0
- Middle East and Africa9.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Sanofi Pasteur | 77 | 81 | 84 | 88 | 96 | 76 | 84 |
| GlaxoSmithKline (GSK) | 86 | 92 | 90 | 90 | 85 | 75 | 86 |
| Bharat Biotech | 82 | 75 | 80 | 76 | 79 | 78 | 78 |
| Serum Institute of India | 67 | 79 | 69 | 65 | 71 | 64 | 69 |
| Mundipharma | 76 | 51 | 56 | 70 | 70 | 75 | 66 |
| Novartis (now part of GSK) | 57 | 62 | 60 | 48 | 59 | 64 | 58 |
| Shantha Biotechnics (a Sanofi company) | 63 | 42 | 56 | 46 | 49 | 48 | 51 |
| Zydus Cadila | 59 | 50 | 52 | 52 | 56 | 45 | 52 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Sanofi Pasteur
- GlaxoSmithKline (GSK)
- Bharat Biotech
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Sanofi Pasteur | ◐ | ◐ | ◐ | ✓ | ✓ | ✓ |
| GlaxoSmithKline (GSK) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Bharat Biotech | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Serum Institute of India | ◐ | ✓ | ✓ | − | ◐ | ◐ |
| Mundipharma | ◐ | − | ◐ | ◐ | ◐ | ◐ |
| Novartis (now part of GSK) | − | − | ◐ | − | − | ◐ |
| Shantha Biotechnics (a Sanofi company) | ◐ | − | ◐ | − | ◐ | − |
| Zydus Cadila | − | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1GlaxoSmithKline (GSK)86
2Sanofi Pasteur84
3Bharat Biotech78
4Serum Institute of India69
5Mundipharma66
6Novartis (now part of GSK)58
7Zydus Cadila52
8Shantha Biotechnics (a Sanofi company)51
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Sanofi PasteurGlaxoSmithKline (GSK)Bharat Biotech
Challenger1
Strong scale, closing on the leaders.
Serum Institute of India
Contender2
Focused players with pockets of strength.
MundipharmaNovartis (now part of GSK)
Niche2
Specialists in a single segment or region.
Shantha Biotechnics (a Sanofi company)Zydus Cadila
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Vaccine Presentation in North America, then scale across Rabies Vaccine (Vero Cell) For Human Use, Freeze-Dried Market — a $470M beachhead inside a $8.00B market.
Beachhead (SOM)$470Mobtainable near-term
Serviceable (SAM)$2.89Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Freeze-Dried Vial
Best fit — highest urgency & budget in Vaccine Presentation.
Economic buyer77 fit
Liquid Ready-to-Use Syringe
Strong fit — clear ROI and a fast path to value.
End user65 fit
Lyophilized Powder
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Vaccine Presentation in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Vaccine Presentation leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Rabies Vaccine (Vero Cell) For Human Use, Freeze-Dried Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified24%
Evaluation14%
Closed-won8%
$11.5KCAC
$52KLTV
4.6:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Rabies Vaccine (Vero Cell) For Human Use, Freeze-Dried Market is a high-growth opportunity — $3.74B by 2033, compounding at 10.0%.
TAM · 2025$1.74Btoday
TAM · 2033$3.74Bforecast
CAGR10.0%2027–2033
Cumulative$23.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.74BTotal addressable market
SAM$1.30BServiceable available market
SOM$251MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.0% CAGR
Demand compounds through 2033, outpacing GDP across Vaccine Presentation.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Vaccine Presentation moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.74BLarge & growingTAM by 2033 at 10.0% CAGR
$1.30BServiceable nowreachable with today’s model
$251MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.92BBear6.5% CAGR
$3.74BBase10.0% CAGR
$4.79BBull13.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Rabies Vaccine (Vero Cell) For Human Use, Freeze-Dried Market — a $9.15B market by 2033. Plan: grow share from 10.0% to 17.9%.
Market size · 2033$9.15Btotal addressable
Market CAGR7.6%2027–2033
Target share17.9%from 10.0% today
Revenue ambition$1.64Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.0% | 17.9% | At risk |
| Revenue | $882M | $1.64B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 34.1% | 42.6% | Ahead |
| Customer retention | 85.0% | 95.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Vaccine Presentation
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Indication capability
A defensible second engine — invest in Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Vaccine Presentation share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $234M capacity & capability investment
- Greenlight bolt-on M&A in Indication
- Authorise North America expansion plan
- Fund R&D program for Vaccine Presentation leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Rabies Vaccine (Vero Cell) For Human Use, Freeze-Dried Market conversation — a $6.54B market you can size, segment and defend in minutes.
Market size · 2033$6.54Btotal opportunity
Growth9.5%CAGR to 2033
Addressable buyers1,228+accounts in scope
Typical ROI6.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Vaccine Presentation
Goal Grow share in Vaccine Presentation
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.1×return on cost, year one
< 3 mopayback period
$96K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Sanofi PasteurGlaxoSmithKline (GSK)Bharat BiotechSerum Institute of IndiaMundipharmaNovartis (now part of GSK)Shantha Biotechnics (a Sanofi company)Zydus Cadila+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Rabies Vaccine (Vero Cell) For Human Use, Freeze-Dried Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Rabies Vaccine (Vero Cell) For Human Use, Freeze-Dried Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →RAC Beta Serine and Threonine Protein Kinase Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportRacemic Repaglinide Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportRacing additive Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportRacing Apparel Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportRacing Bicycle Market
Market size, share, segmentation and regional forecast.
$433M market · 2025 base year
View reportRacing Drones Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportRacing fuel additive Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportracing fuel Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportRacing Gloves And Racing Suits Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportRacing Machine Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportRacing Pedals Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportRacing Tire Market
Market size, share, segmentation and regional forecast.
$351M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.